Conestoga Capital Advisors, an asset management company, recently released its first-quarter 2026 investor letter. The letter highlighted the challenges faced in the first quarter, including volatility stemming from Middle East geopolitical unrest and shifting interest rate expectations. These factors led to a cautious global market environment, with energy prices rising and creating uncertainty.
During this period, certain sectors such as Energy, Basic Materials, and Industrials performed well, while software companies encountered difficulties due to concerns about AI disruption. The market remained sensitive to geopolitical events, energy prices, and inflation, contributing to heightened volatility. The Conestoga Small Cap Composite experienced a decline of 5.01%, underperforming the Russell 2000 Growth index’s return of -2.81%. This decline was attributed to negative stock selection and challenges in the Technology and Health Care sectors.
In its investor letter, Conestoga Capital Advisors highlighted Stevanato Group S.p.A. (NYSE:STVN) as a noteworthy stock. Stevanato Group is an Italian company that provides products and solutions for the biopharma and healthcare industries. Despite facing challenges in the first quarter, the company showed resilience, with a one-month return of 20.12% and a market capitalization of approximately $4.42 billion.
According to Conestoga Capital Advisors, Stevanato Group faced struggles as investors assessed its solid results against a mixed business mix and moderating growth profile. While the company saw improvements in margins and the scaling of high-value solutions, overall revenue growth remained modest at 5% in the quarter. Weakness in the Engineering segment and a shift towards higher value products contributed to a tempered market reaction. Additionally, factors such as the decline of oral vs. GLP-1s added pressure on the stock.
Despite its potential, Stevanato Group S.p.A. (NYSE:STVN) is not among the 40 Most Popular Stocks Among Hedge Funds for 2026. However, 15 hedge fund portfolios held the stock at the end of the fourth quarter, indicating some interest from investors. In Q4 2025, the company’s revenue grew by 7% at constant currency and 5% on a reported basis, reaching $346.5 million.
While Stevanato Group shows promise as an investment, Conestoga Capital Advisors believes that certain AI stocks may offer greater upside potential with lower downside risk. For investors seeking opportunities in the AI sector, exploring undervalued stocks with potential for growth could be a rewarding strategy. Overall, the first-quarter investor letter from Conestoga Capital Advisors provides valuable insights into the market landscape and potential investment opportunities for the future.
